We meta-analyzed the three case-control studies of GLP-1 RA users versus those on other second-line diabetes medication and found a reduced dementia risk (RR = 0.73[0.54, 0.99], I2 = 96%) (Figure 2).30,33,36. Here, GLP1R is linked to diabetes mellitus.